01.02.14 - DxNA concludes the acquisition of PathoGene,LLC.
11.19.13 - DxNA receives an equity investment to proceed with the regulatory processes for the 510(k) clearance of two assays.
7.17.13 - DxNA announces the completion of the Staph - MRSA+ assay licence agreement with Pathogene, LLC and a letter of intent to acquire Pathogene, LLC.
05.21.13 - KUTV airs news of the DxNA and Pathogene agreement on the Staph - MRSA+ assay.http://www.kutv.com/news/top-stories/stories/vid_5043.shtml
05.08..13 - DxNA acquires exclusive licence for Pathogene,LLC's next generation Staph - MRSA+ assay
03.21.13 - BSI America issues DxNA an ISO 13485:2003 recertification.